HSBC has upgraded AbbVie Inc (ABBV) to a Buy rating from Hold, signaling a more optimistic outlook on the company's future. This upgrade, effective December 9, 2025, comes as AbbVie continues to navigate the biotechnology landscape with a robust portfolio that includes immunology, oncology, aesthetics, neuroscience, and eye care products.
The current price of AbbVie shares stands at $224.07, and the company's market capitalization is approximately $394.3 billion. AbbVie boasts a P/E ratio of 165.13 and an earnings per share (EPS) of 1.35, alongside a notable dividend yield of 310.1%.
Analyst ratings, such as this upgrade, reflect professional assessments based on extensive research and financial modeling. While they provide valuable insights into a company's perceived value, they also depend on various assumptions that may not always hold true. Investors are encouraged to consider a range of factors, including company fundamentals, competitive positioning, and industry trends, when making decisions.
AbbVie is scheduled to announce its next earnings report on July 29, 2026, with estimates of $3.71 EPS and $16.9 billion in revenue. Recent performance has shown positive surprises in earnings, including a Q3 2025 EPS of $1.86, exceeding expectations by 2.7%. As analyst opinions can shift with new information, this upgrade reflects a significant moment in AbbVie's ongoing assessment by market experts.